0001769177-20-000003.txt : 20201117
0001769177-20-000003.hdr.sgml : 20201117
20201117143322
ACCESSION NUMBER: 0001769177-20-000003
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20201117
DATE AS OF CHANGE: 20201117
EFFECTIVENESS DATE: 20201117
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: GENEOS Therapeutics, Inc.
CENTRAL INDEX KEY: 0001769177
IRS NUMBER: 813107759
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-380790
FILM NUMBER: 201320664
BUSINESS ADDRESS:
STREET 1: 660 WEST GERMANTOWN PIKE
STREET 2: SUITE LL110
CITY: PLYMOUTH MEETING
STATE: PA
ZIP: 19462
BUSINESS PHONE: 267-440-4232
MAIL ADDRESS:
STREET 1: 660 WEST GERMANTOWN PIKE
STREET 2: SUITE LL110
CITY: PLYMOUTH MEETING
STATE: PA
ZIP: 19462
D
1
primary_doc.xml
X0708
D
LIVE
0001769177
GENEOS Therapeutics, Inc.
660 WEST GERMANTOWN PIKE
SUITE LL110
PLYMOUTH MEETING
PA
PENNSYLVANIA
19462
267-440-4232
DELAWARE
Aeneos Therapeutics, Inc.
None
Corporation
true
2016
Niranjan
Y.
Sardesai
c/o GENEOS Therapeutics, Inc.
660 West Germantown Pike, Suite LL110
Plymouth Meeting
PA
PENNSYLVANIA
19462
Executive Officer
Director
James
Eadie
c/o GENEOS Therapeutics, Inc.
660 West Germantown Pike, Suite LL110
Plymouth Meeting
PA
PENNSYLVANIA
19462
Director
J.
Joseph
Kim
c/o GENEOS Therapeutics, Inc.
660 West Germantown Pike, Suite LL110
Plymouth Meeting
PA
PENNSYLVANIA
19462
Director
Casey
Cunningham
c/o GENEOS Therapeutics, Inc.
660 West Germantown Pike, Suite LL110
Plymouth Meeting
PA
PENNSYLVANIA
19462
Director
Samuel
Broder
c/o GENEOS Therapeutics, Inc.
660 West Germantown Pike, Suite LL110
Plymouth Meeting
PA
PENNSYLVANIA
19462
Director
Sangwoo
Lee
c/o GENEOS Therapeutics, Inc.
660 West Germantown Pike, Suite LL110
Plymouth Meeting
PA
PENNSYLVANIA
19462
Director
Biotechnology
Decline to Disclose
- 06b
false
2020-11-12
false
true
false
0
11999995
10399998
1599997
false
4
0
0
0
false
GENEOS Therapeutics, Inc.
/s/ Niranjan Y. Sardesai
Niranjan Y. Sardesai
President and Chief Executive Officer
2020-11-17